In the news

  • Korro Bio’s $91.5M Series A brings in new investors, launches hunt for CEO

    • BioCentury – September 10, 2020
    • Read more

  • A knight at the OPERA? Kraken the RNA code, Korro on (r)ADAR with $91.5M Series A

  • Biotech plans first drug trial, C-suite hiring push after $91.5M round

    • Boston Business Journal – September 10, 2020
    • Read more

  • Korro banks $91.5M for RNA editing push

  • Korro Bio closes $91.5M Series A financing

  • VC Daily: Korro Bio gets $91.5 million

    • The Wall Street Journal – September 10, 2020
    • Read more

  • Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play

    • Endpoints News – September 10, 2020
    • Read more

  • Korro Bio hits the high notes with $91.5M Series A to run its OPERA RNA platform

    • FierceBiotech – September 10, 2020
    • Read more

  • Korro Bio raises $90m to fix mutations that cause diseases

    • The Boston Globe – September 10, 2020
    • Read more

  • Nature Biotechnology’s academic spinouts of 2019

    • Nature Biotechnology – April 23, 2020
    • Read more

  • Gene editing vets launch Korro to convert RNA bases

  • Atlas Venture, NEA back RNA-editing startup Korro Bio

    • Wall Street Journal – October 7, 2019
    • Read more

  • Atlas unveils RNA-editing Korro Bio helmed by Nessan Bermingham

    • FierceBiotech – October 7, 2019
    • Read more

  • Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio

  • New Cambridge biotech Korro aims to develop a reversible form of gene editing

    • Boston Business Journal – October 7, 2019
    • Read more